Skip to main content
KI

KaloCyte, Inc.

KaloCyte is developing ErythroMer, a dried, bio-inspired artificial red blood cell designed to treat life-threatening blood loss when stored red blood cells are unavailable or undesirable. This technology aims to address the critical need for transfusion alternatives in pre-hospital settings and during mass casualty events.

Founded 2016192K+ followers
Updated 20 months ago

Funding

$5K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

CR
Funding rounds are not available yet.

Founders

Product

Problem

In situations involving significant blood loss, the immediate availability of compatible red blood cells for transfusion is often limited, especially in pre-hospital settings, remote locations, and mass casualty events. Reliance on stored blood products carries risks of immune reactions and may not always meet the demand, leading to preventable deaths.

Solution

KaloCyte is developing ErythroMer, a bio-inspired artificial red blood cell designed to function as a transfusion alternative when donor blood is unavailable, undesirable, or in short supply. ErythroMer is a freeze-dried powder consisting of nano-encapsulated human hemoglobin coated with a synthetic polymer. This coating enables the artificial cells to effectively capture and release oxygen in response to blood pH levels, mimicking the behavior of natural red blood cells. ErythroMer can be stored at ambient temperatures for extended periods and quickly reconstituted with sterile water for immediate use. The resulting solution is blood-type agnostic, designed to provide oxygen-carrying support until conventional blood transfusions become accessible.

Target Audience

The primary target audience includes paramedics, military medics, emergency room personnel, and healthcare providers in resource-limited settings who require a readily available solution for treating hemorrhagic shock.

Features

  • Lyophilized (freeze-dried) powder formulation for long-term storage and rapid reconstitution
  • Nano-encapsulated human hemoglobin to ensure oxygen-carrying capacity
  • Synthetic polymer coating that responds to blood pH, facilitating oxygen release in tissues
  • Immune-silent design, enabling use across all blood types
  • Designed for field deployment in challenging environments, including pre-hospital and combat settings
This profile is AI-generated and may contain inaccuracies.